GC
INFI

Gratus Capital’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Gratus Capital’s Portfolio INFI Stock Details INFI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,323,598
Closed -$735K – 250
2022
Q4 		$735K Buy
1,323,598
+74,350
+6% +$63.2K 0.06% 143
2022
Q3 		$1.49M Buy
1,249,248
+132,094
+12% +$142K 0.16% 100
2022
Q2 		$706K Buy
1,117,154
+85,750
+8% +$65.8K 0.08% 119
2022
Q1 		$1.18M Buy
1,031,404
+74,532
+8% +$89.1K 0.11% 108
2021
Q4 		$2.15M Buy
+956,872
New +$2.4M 0.2% 83

Other funds holding INFI

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Gratus Capital's INFI Position: Q1 2023 in Review

Gratus Capital sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q1 2023, closing a stake of 1,323,598 shares — an estimated $735K sold.

Gratus Capital first reported a position in INFI in Q4 2021 and held it in 5 quarters. The position peaked at $2.15M in Q4 2021. 53 funds tracked by Wall St. Rank hold INFI as of Q1 2023.

  • Gratus Capital reported no remaining Infinity Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
  • Gratus Capital sold 1,323,598 Infinity Pharmaceuticals, Inc. shares in Q1 2023, an estimated $735K.
  • Gratus Capital first reported a position in Infinity Pharmaceuticals, Inc. in Q4 2021 and held it in 5 quarters.
  • Gratus Capital's Infinity Pharmaceuticals, Inc. position peaked at $2.15M in Q4 2021.
  • 53 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q1 2023.

Based on Gratus Capital's 13F filing for Q1 2023, filed 20 Apr 2023.